AGER and myeloid sarcoma: Interestingly, one small study of MS patients found that 12-month treatment with fingolimod increased serum levels of soluble RAGE isoforms, which are known to inhibit RAGE signaling, and decreased the rate of clinical relapse.25 At least some of the beneficial effect of fingolimod may be through modulation of the RAGE axis.